1. |
Comert S, Dogan C, Fidan A, et al. The correlation of different pneumonia severity classifications with each other according to the indications for hospitalization. Turk Toraks Dergisi, 2013, 13(4): 158-162.
|
2. |
Chalmers JD, Singanayagam A, Murray MP, et al. Risk factors for complicated parapneumonic effusion and empyema on presentation to hospital with community-acquired pneumonia. Thorax, 2009, 64(7): 592-597.
|
3. |
Karkhanis VS, Joshi JM. Pleural effusion: diagnosis, treatment, and management. Open Access Emerg Med, 2012, 4: 31-52.
|
4. |
Corcoran JP, Wrightson JM, Belcher E, et al. Pleural infection: past, present, and future directions. Lancet Respir Med, 2015, 3(7): 563-577.
|
5. |
Rosenstengel A. Pleural infection-current diagnosis and management. J Thorac Dis, 2012, 4(2): 186-193.
|
6. |
Luna CM, Palma I, Niederman MS, et al. The impact of age and comorbidities on the mortality of patients of different age groups admitted with community-acquired pneumonia. Ann Am Thorac Soc, 2016, 13(9): 1519-1526.
|
7. |
中华医学会呼吸病学分会. 中国成人社区获得性肺炎诊断和治疗指南(2016 年版). 中华结核和呼吸杂志, 2016, 39(4): 253-279.
|
8. |
Han X, Zhou F, Li H, et al. Effects of age, comorbidity and adherence to current antimicrobial guidelines on mortality in hospitalized elderly patients with community-acquired pneumonia. BMC Infect Dis, 2018, 18(1): 192-203.
|
9. |
Uh S, Lee SM, Kim HT, et al. The effect of radiation therapy on immune function in patients with squamous cell lung carcinoma. Chest, 1994, 105(1): 132-137.
|
10. |
陈亮, 韩秀迪, 邢西迁, 等. 合并慢性阻塞性肺疾病的社区获得性肺炎住院患者临床特征和预后因素分析. 中国呼吸与危重监护杂志, 2019, 18(5): 409-417.
|
11. |
Chen L, Zhou F, Li H, et al. Disease characteristics and management of hospitalised adolescents and adults with community-acquired pneumonia in China: a retrospective multicentre survey. BMJ Open, 2018, 8(2): e018709.
|
12. |
Light RW. Parapneumonic effusions and empyema. Proc Am Thorac Soc, 2006, 3(1): 75-80.
|
13. |
Dean NC, Griffith PP, Sorensen JS, et al. Pleural effusions at first ED encounter predict worse clinical outcomes in patients with pneumonia. Chest, 2016, 149(6): 1509-1515.
|
14. |
Petrusevska-Marinkovic S, Kondova-Topuzovska I, Milenkovic Z, et al. Clinical, laboratory and radiographic features of patients with pneumonia and parapneumonic effusions. Open Access Maced J Med Sci, 2016, 4(3): 428-434.
|
15. |
Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med, 2008, 121(3): 219-225.
|
16. |
Li D, Shen Y, Qin J, et al. Diagnostic performance of C-reactive protein for parapneumonic pleural effusion: a meta-analysis. Ann Transl Med, 2019, 7(1): 1.
|
17. |
Skouras V, Boultadakis E, Nikoulis D, et al. Prognostic value of C-reactive protein in parapneumonic effusions. Respirology, 2012, 17(2): 308-314.
|
18. |
Shimon I, Wasser WG, Fox BD, et al. The diagnostic value of the pleural fluid C-reactive protein in parapneumonic effusions. Dis Markers, 2016, 2016: 1-6.
|
19. |
Marinkovic SP, Topuzovska IK, Milenkovic Z, et al. The role of serum coagulation factors in the differential diagnosis of patients with pneumonia and parapneumonic effusion. Pril (Makedon Akad Nauk Umet Odd Med Nauki), 2016, 37(2-3): 81-88.
|
20. |
Porcel JM, Valencia H, Bielsa S. Factors influencing pleural drainage in parapneumonic effusions. Rev Clin Esp, 2016, 216(7): 361-366.
|
21. |
Porcel JM, Bielsa S, Esquerda A, et al. Pleural fluid C-reactive protein contributes to the diagnosis and assessment of severity of parapneumonic effusions. Eur J Intern Med, 2012, 23(5): 447-450.
|
22. |
Tsang KY, Leung WS, Chan VL, et al. Complicated parapneumonic effusion and empyema thoracis: microbiology and predictors of adverse outcomes. Hong Kong Med J, 2007, 13(3): 178-186.
|
23. |
Meyer CN, Rosenlund S, Nielsen J, et al. Bacteriological aetiology and antimicrobial treatment of pleural empyema. Scand J Infect Dis, 2011, 43(3): 165-169.
|
24. |
Kim J, Park JS, Cho YJ, et al. Predictors of prolonged stay in patients with community-acquired pneumonia and complicated parapneumonic effusion. Respirology, 2016, 21(1): 164-171.
|
25. |
Brims F, Popowicz N, Rosenstengel A, et al. Bacteriology and clinical outcomes of patients with culture-positive pleural infection in Western Australia: A 6-year analysis. Respirology, 2019, 24(2): 171-178.
|
26. |
Lin YT, Chen TL, Siu LK, et al. Clinical and microbiological characteristics of community-acquired thoracic empyema or complicated parapneumonic effusion caused by Klebsiella pneumoniae in Taiwan. Eur J Clin Microbiol Infect Dis, 2010, 29(8): 1003-1010.
|
27. |
Melot B, Colot J, Guerrier G. Bacteremic community-acquired infections due to klebsiella pneumoniae: clinical and microbiological presentation in New Caledonia, 2008-2013. Int J Infect Dis, 2015, 41: 29-31.
|
28. |
Maskell NA, Davies CWH, Nunn AJ, et al. U.K. Controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med, 2005, 352(9): 865-874.
|
29. |
Park CK, Oh HJ, Choi HY, et al. Microbiological characteristics and predictive factors for mortality in pleural infection: a single-center cohort study in korea. PLoS One, 2016, 11(8): e0161280.
|
30. |
Cilloniz C, Polverino E, Ewig S, et al. Impact of age and comorbidity on cause and outcome in community-acquired pneumonia. Chest, 2013, 144(3): 999-1007.
|
31. |
Sahuquillo-Arce JM, Menendez R, Mendez R, et al. Age-related risk factors for bacterial aetiology in community-acquired pneumonia. Respirology, 2016, 21(8): 1472-1479.
|
32. |
Ceccato A, Torres A, Cilloniz C, et al. Invasive disease vs urinary antigen-confirmed pneumococcal community-acquired pneumonia. Chest, 2017, 151(6): 1311-1319.
|
33. |
Bagshaw SM, Laupland KB, Doig CJ, et al. Prognosis for long-term survival and renal recovery in critically ill patients with severe acute renal failure: a population-based study. Crit Care, 2005, 9(6): R700-709.
|
34. |
Su G, Xu H, Riggi E, et al. Association of kidney function with infections by multidrug-resistant organisms: an electronic medical record analysis. Sci Rep, 2018, 8(1): 176-178.
|
35. |
Wonnacott A, Meran S, Amphlett B, et al. Epidemiology and outcomes in community-acquired versus hospital-acquired AKI. Clin J Am Soc Nephrol, 2014, 9(6): 1007-1014.
|
36. |
Zeng X, McMahon GM, Brunelli SM, et al. Incidence, outcomes, and comparisons across definitions of AKI in hospitalized individuals. Clin J Am Soc Nephrol, 2014, 9(1): 12-20.
|